Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 9Carcinoma, Renal Cell 8Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Recurrence 3Glioblastoma 3Carcinoma, Neuroendocrine 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neuroendocrine Tumors 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Diseases 1

Interventions

pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vorinostat 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumour × avelumab × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡